Digital Health US

US AI in Clinical Trials Market Analysis, 2024–2034

Updated Reviewed by Vidhi Upadhyay

US AI in Clinical Trials Market Industry Trends and Forecast to 2034: Segmented by (Application, Phase, End User, Region) - Growth, Market Size, Future Prospects & Competitive Analysis, 2024-2034

Overview

Market Dashboard

US · 2024–2034 · placeholder estimates

Values shown here are placeholder estimates, not researched figures. Researched 2024 historical, 2025 base-year and 2026–2034 forecast values are prepared with the full report.

Estimate 2024 $820.6 Mn Placeholder estimate
Estimate 2025 $1.00 Bn 46.5% of the global market
Projected 2034 $6.04 Bn 503.2% Adds $5.04 Bn over 9 forecast years
CAGR 2025–2034 22.1% Faster than 79% of 100 Digital Health markets here
Key players 5 Companies profiled
  • US is 46.55% of the global market.
  • In North America, the largest is US (this report) at $1.00 Bn.
  • Fastest growing: Canada at 23.7% a year.
  • US ranks 1st of 2 by size in North America.

Market size projection

US

Source: Acuitas Health Analytics. Full methods, sources and usage terms come with report purchase.

Value added each year

$5.04 Bn total, 2026–2034

Year-by-year market size, 2024–2034
AI in Clinical Trials Market market size by year, US
YearMarket sizeChange that yearSince 2025
2024 (estimate) $820.6 Mn — —
2025 (base) $1.00 Bn +$181.4 Mn —
2026 (forecast) $1.22 Bn +$221.4 Mn +22.1%
2027 (forecast) $1.49 Bn +$270.4 Mn +49.1%
2028 (forecast) $1.82 Bn +$330.1 Mn +82%
2029 (forecast) $2.23 Bn +$403.1 Mn +122.3%
2030 (forecast) $2.72 Bn +$492.2 Mn +171.4%
2031 (forecast) $3.32 Bn +$600.9 Mn +231.4%
2032 (forecast) $4.05 Bn +$733.8 Mn +304.6%
2033 (forecast) $4.95 Bn +$895.9 Mn +394%
2034 (forecast) $6.04 Bn +$1.09 Bn +503.2%

Placeholder estimates. Each year is projected from our earlier market estimate and its CAGR. Researched values come with the full report.

Report snapshot

US AI in Clinical Trials Market Analysis at a glance
Market size, 2025$1.00 Bn placeholder estimate
Forecast, 2034$6.04 Bn placeholder estimate
Growth (CAGR), 2025–203422.1% placeholder estimate
Years2024 historical · 2025 base year · 2026–2034 forecast
SegmentsApplication, phase and end user (see all)
Key playersIQVIA, Medidata (Dassault Systemes), Unlearn.AI, Deep 6 AI, Saama Technologies (see all)
Regulator in the USFDASource: US Food and Drug Administration. Checked 14 Nov 2026.
FormatsPDF, PPTX, XLSX

Sizes and growth here are placeholder estimates, not researched figures. Researched figures come with the full report.

The US AI in Clinical Trials Market Analysis Executive Summary

AI in clinical trials helps design studies, find suitable patients, choose sites and analyse results faster.

Key segments of the AI in Clinical Trials market include application (Patient Recruitment, Trial Design and Site Selection) and phase (Phase I, Phase II and Phase III).

Bar chart: US AI in Clinical Trials market size, 2024–2034, placeholder estimates. $820.6 Mn in 2024, $1.00 Bn in 2025 and $6.04 Bn in 2034, 22.1% CAGR.
US AI in Clinical Trials market size, 2024–2034. Placeholder estimates; researched figures come with the full report. Source: Acuitas Health Analytics.

US AI in Clinical Trials Market Dynamics

Market Growth Drivers

Advances in machine learning and large language models, more digital health data, clinician shortages and pressure to cut costs are driving the AI in Clinical Trials market. Health systems are moving from pilots to wider use.

Opportunity

Generative AI, automation of paperwork and AI tools approved as medical devices give the AI in Clinical Trials market strong growth, including in emerging health systems.

Market Restraints

Concerns about accuracy, bias, privacy and liability, along with unclear regulation and the cost of fitting AI into clinical workflows, hold back the AI in Clinical Trials market.

Competitive Landscape for AI in Clinical Trials Market in the US

The AI in Clinical Trials market is moderately concentrated. Leading companies compete on product innovation, clinical evidence, pricing and geographic reach, and use partnerships and acquisitions to expand their portfolios.

Key Players

Healthcare Policies and Regulatory Landscape for AI in Clinical Trials Market in the US

AI in Clinical Trials in the US: rules and payment

The FDA regulates software that works as a medical device, and runs a Digital Health Center of Excellence.⁠[1] Medicare covers people aged 65 and over and some younger people with disabilities, and Medicaid covers many people on low incomes; both are run with the Centers for Medicare & Medicaid Services (CMS).⁠[2]

[1] US Food and Drug Administration. Checked 14 Nov 2026.

[2] Centers for Medicare & Medicaid Services. Checked 14 Nov 2026.

Policy changes and Reimbursement scenario

Rules on software as a medical device, data privacy (such as HIPAA and GDPR) and telehealth reimbursement shape the AI in Clinical Trials market. Government digital health programs in the US are speeding up adoption.

Beyond the market numbers

Research, trials and patients

What doctors and scientists are doing in AI in Clinical Trials right now, from free public sources.

Sources: PubMed (US National Library of Medicine), ClinicalTrials.gov, World Bank. Fetched 12 Nov 2026. Papers and trials are found by search words, so the counts are a guide. Titles only; read each paper at its source.

Public data, with sources

AI in Clinical Trials in context

The US compared

  • Health spending per person: 13,473 US$ per person (2023). World: 1,317 US$ per person (2023).[1]
  • Doctors: 3.68 per 1,000 people (2022). World: 1.86 per 1,000 people (2022).[2]
  • People aged 65 and over: 18.4% of people (2025). World: 10.4% of people (2025).[3]

[1] World Bank Open Data, Health spending per person (US$ per person). Retrieved 19 Nov 2026.

[2] World Bank Open Data, Doctors (per 1,000 people). Retrieved 20 Nov 2026.

[3] World Bank Open Data, People aged 65 and over (% of people). Retrieved 19 Nov 2026.

Free data on this topic

Quick answers

Frequently asked questions

How big is the AI in Clinical Trials market in the US?
Placeholder estimate: about $1.00 Bn in 2025, rising to about $6.04 Bn by 2034. These are early estimates, not researched figures; the researched values come with the full report.
How fast is the AI in Clinical Trials market in the US growing?
Placeholder estimate: about 22.1% a year (CAGR, 2025–2034). The researched growth rate comes with the full report.
What segments does the AI in Clinical Trials market report cover?
The report splits the market by application (Patient Recruitment, Trial Design, Site Selection, Data Analysis), phase (Phase I, Phase II, Phase III) and end user (Healthcare Providers, Patients, Payers, Pharmaceutical Companies).
Who are the key players in the AI in Clinical Trials market?
Key players include IQVIA, Medidata (Dassault Systemes), Unlearn.AI, Deep 6 AI and Saama Technologies.
What is driving the AI in Clinical Trials market?
Advances in machine learning and large language models, more digital health data, clinician shortages and pressure to cut costs are driving the AI in Clinical Trials market. Health systems are moving from pilots to wider use.
Who regulates AI in Clinical Trials in the US?
The FDA regulates software that works as a medical device, and runs a Digital Health Center of Excellence. Source: US Food and Drug Administration. Checked 14 Nov 2026.
How is healthcare paid for in the US?
Medicare covers people aged 65 and over and some younger people with disabilities, and Medicaid covers many people on low incomes; both are run with the Centers for Medicare & Medicaid Services (CMS). Source: Centers for Medicare & Medicaid Services. Checked 14 Nov 2026.
How much research is published on AI in Clinical Trials?
PubMed lists 739 papers on AI in Clinical Trials added since January 2021, worldwide. Source: PubMed, Papers added since 1 January 2021 matching this market. Retrieved 12 Nov 2026.
Back to Catalogue

Related Digital Health reports in US

See all

Related on artificial intelligence and clinical trials

See the topic